Latest Breaking News On - Disc medicine - Page 1 : comparemela.com

Disc Medicine (NASDAQ:IRON) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $85.00 price objective on the stock. Several other equities research analysts also recently commented on the company. Morgan Stanley reduced their target price on Disc […]

United statesRaymond jamesStifel nicolausWilliam richard whiteCharles schwab investment management incMorgan stanleyDisc medicine company profileYork mellon corpBarclays plcDisc medicine incCantor fitzgeraldSwiss national bankVictory capital management incDisc medicineFree reportModerate buy

Disc Medicine s (IRON) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $85.00 target price on the stock. IRON has been the subject of a number of other reports. Wedbush reaffirmed an outperform rating and set a $43.00 price […]

United statesRaymond jamesWilliam richard whiteStifel nicolausJennison associatesDisc medicine company profileVictory capital management incCantor fitzgeraldPricet rowe associates incDisc medicine incFirst turn managementDisc medicineFree reportModerate buyGet free reportDirector william richard white

Monoclonal Antibody Investigated for Anemia of CKD

Monoclonal Antibody Investigated for Anemia of CKD
renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomLong beachNational kidney foundationClinical meetingsWill savageDisc medicine

Disc Medicine (NASDAQ:IRON) Stock Rating Reaffirmed by Cantor Fitzgerald

Disc Medicine (NASDAQ:IRON – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $85.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 148.97% from the company’s current price. Several […]

United statesRaymond jamesWilliam richard whiteDisc medicine incMorgan stanleyBleakley financial groupChina universal asset management coProshare advisorsCantor fitzgeraldSecurities exchange commissionDisc medicineGet free reportDirector william richard whiteExchange commissionUniversal asset managementShare advisors

Disc Medicine s (IRON) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $85.00 price target on the stock. Several other research analysts have also weighed in on IRON. Stifel Nicolaus upped their price target on Disc Medicine from […]

United statesStifel nicolausRaymond jamesWilliam richard whiteSecurities exchange commissionCharles schwab investment management incVictory capital management incDisc medicine incSwiss national bankBarclays plcYork mellon corpCantor fitzgeraldDisc medicineFree reportModerate buyGet free report